Anlotinib helps alleviate radiation pneumonitis: A case report
Precision Radiation Oncology2021Vol. 5(4), pp. 256–258
Citations Over Time
Abstract
Abstract Radiation pneumonitis is a serious side effect of thoracic radiotherapy with no established treatment currently. Anlotinib is a small‐molecule tyrosine kinase inhibitor (TKI) with anti‐angiogenic effects. The effect of TKIs in the treatment of radiation pneumonitis remains to be elucidated. We investigated whether anlotinib could alleviate radiation pneumonitis. We report a case of a patient with esophageal cancer who received anlotinib for radiation pneumonitis following radiotherapy. We also reviewed related studies to address this issue. The results in this patient suggest that anlotinib may be a valid treatment option for radiation pneumonitis.
Related Papers
- → Surfactant release as an early measure of radiation pneumonitis(1983)60 cited
- → Age factor relevant to the development of radiation pneumonitis in radiotherapy of lung cancer(1988)43 cited
- Partial frequency of radiation pneumonitis and its association with the energy and treatment technique in patients with breast cancer, Isfahan, Iran.(2013)
- [Clinical study of radiation pneumonitis over 10 years].(1995)
- → Altered regional clearance of 99Tcm-DTPA in radiation pneumonitis(1992)8 cited